Dalteparin
Title: Dalteparin
Additional Names: Tedelparin
Literature References: Low molecular weight fragment of heparin, q.v., prepd by nitrous acid depolymerization of porcine mucosal heparin. Mean mol wt 4000-6000 daltons. Prepn: U. Lindahl et al., WO 8001383; eidem, US 4303651 (1980, 1981 both to Kabi AB). See also: eidem, Proc. Natl. Acad. Sci. USA 76, 3198 (1979). Comparison of bioactivity with standard heparin: E. Holmer et al., Thromb. Res. 18, 861 (1980). Clinical pharmacokinetics: G. Bratt et al., ibid. 42, 613 (1986). Symposia on pharmacology and clinical efficacy: Haemostasis 16, Suppl. 2, 1-71 (1986); Semin. Thromb. Hemostasis 16, Suppl., 1-76 (1990). Clinical trial in unstable angina: W. Klein et al., Circulation 96, 61 (1997); in unstable coronary artery disease: FRISC II Investigators, Lancet 354, 701 (1999). Review: C. J. Dunn, E. M. Sorkin, Drugs 52, 276-305 (1996).
 
Derivative Type: Sodium salt
Manufacturers' Codes: Kabi 2165; FR-860
Trademarks: Boxol (Pharmacia & Upjohn); Fragmin (Pharmacia & Upjohn)
 
Therap-Cat: Antithrombotic.
Keywords: Antithrombotic.

Others monographs:
Spirit of Ether Compound1-OctanolChlorobenzilateLiatris
MebrofeninFluazacort2-p-SulfanilylanilinoethanolCloprostenol
CefotiamMetoclopramideEosine I BluishFerumoxides
CarbinoxamineTrastuzumabAcetophenoneVacciniin
©2016 DrugLead US FDA&EMEA